Want to see DNLI full AI Analyst Report?
Top Page
Denali Therapeutics
(NASDAQ:DNLI)
Select Model
Select Model
Rating:56Neutral
Price Target:
$27.00
▲(31.26% Upside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial performance (no recent revenue, large ongoing losses, and high cash burn) despite a comparatively solid, low-debt balance sheet. Technicals are currently favorable with strong trend/momentum, while corporate events are mixed—major FDA approval and funding positives offset by a significant clinical trial failure. Valuation is difficult to support using P/E due to losses and there is no dividend yield provided.
Positive Factors
Proprietary BBB TransportVehicle platform
Denali’s TransportVehicle platform is a structural competitive advantage: enabling blood–brain barrier delivery addresses a persistent biomedical bottleneck, supports multiple indications (neurodegenerative and lysosomal), attracts partners, and creates scalable R&D optionality that remains relevant over months as programs advance.
Negative Factors
Large negative cash flow and high burn
Persistently negative operating and free cash flow at roughly half a billion annualized implies ongoing funding needs; absent durable revenue, the company must repeatedly access markets, partners, or sell assets, increasing dilution risk and constraining sustained multi-program development without new cash sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary BBB TransportVehicle platform
Denali’s TransportVehicle platform is a structural competitive advantage: enabling blood–brain barrier delivery addresses a persistent biomedical bottleneck, supports multiple indications (neurodegenerative and lysosomal), attracts partners, and creates scalable R&D optionality that remains relevant over months as programs advance.
Read all positive factors
Denali Therapeutics (DNLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.75B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue GrowthN/A
EPS Growth-7.88%
CountryUS
Employees443
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.88
Shares Outstanding158,709,730
10 Day Avg. Volume2,021,565
30 Day Avg. Volume1,962,924
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.91Price Target Upside69.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.48
Revenue Forecast (FY)$34.99M
Denali Therapeutics Business Overview & Revenue Model
Company Description
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initi...
How the Company Makes Money
Denali primarily makes money through (1) collaboration and licensing arrangements with large pharmaceutical partners and (2) to a lesser extent, other collaboration-related income; it is not consistently reliant on commercial product sales because...
Denali Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 330.53M | 108.46M | 48.66M |
| Gross Profit | -5.71M | -11.18M | 0.00 | 330.53M | 108.46M | 48.66M |
| EBITDA | -493.47M | -497.63M | -492.89M | -128.47M | -315.59M | -282.56M |
| Net Income | -508.02M | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M |
Balance Sheet | ||||||
| Total Assets | 1.27B | 1.14B | 1.37B | 1.15B | 1.46B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 987.68M | 867.88M | 832.33M | 1.03B | 1.34B | 865.41M |
| Total Debt | 40.05M | 36.76M | 48.71M | 52.24M | 60.35M | 64.01M |
| Total Liabilities | 339.93M | 131.09M | 144.50M | 122.96M | 417.81M | 441.87M |
| Stockholders Equity | 926.10M | 1.01B | 1.23B | 1.03B | 1.04B | 962.29M |
Cash Flow | ||||||
| Free Cash Flow | -419.23M | -422.10M | -363.61M | -370.93M | -262.55M | -219.89M |
| Operating Cash Flow | -412.34M | -412.60M | -347.69M | -357.99M | -244.72M | -211.39M |
| Investing Cash Flow | 330.99M | 255.28M | -88.76M | 249.31M | -141.39M | -21.63M |
| Financing Cash Flow | 412.02M | 189.22M | 484.30M | 17.82M | 310.67M | 19.35M |
Denali Therapeutics Technical Analysis
Positive
20.57
Price Trends
22.26
Positive
21.15
Positive
19.55
Positive
Market Momentum
0.20
Positive
49.10
Neutral
27.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNLI, the sentiment is Positive. The current price of 20.57 is below the 20-day moving average (MA) of 24.94, below the 50-day MA of 22.26, and above the 200-day MA of 19.55, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 49.10 is Neutral, neither overbought nor oversold. The STOCH value of 27.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNLI.
Denali Therapeutics Risk Analysis
Denali Therapeutics disclosed 75 risk factors in its most recent earnings report. Denali Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Denali Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $3.49B | -1,423.44 | -1.41% | ― | 95.29% | 98.21% | |
65 Neutral | $3.33B | -22.93 | -13.96% | ― | 3118.14% | 55.95% | |
56 Neutral | $3.75B | -8.13 | -52.20% | ― | ― | -7.88% | |
55 Neutral | $2.14B | -5.00 | -34.11% | ― | 78.34% | -161.91% | |
55 Neutral | $4.40B | -22.71 | -244.61% | ― | ― | -28.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.74B | -40.48 | -5.89% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
DNLI
Denali Therapeutics
23.42
9.11
63.66%
AGIO
Agios Pharma
36.28
-3.37
-8.50%
CELC
Celcuity
88.34
74.29
528.75%
IDYA
IDEAYA Biosciences
36.23
11.40
45.91%
ARQT
Arcutis Biotherapeutics
27.33
12.31
81.96%
BEAM
Beam Therapeutics
25.91
4.96
23.68%
Denali Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Denali Monetizes FDA Voucher to Advance CNS Pipeline
Positive
Jun 18, 2026
On June 12, 2026, Denali Therapeutics entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher awarded by the U.S. FDA after the March 2026 accelerated approval of AVLAYAH for Hunter syndrome. The buyer wil...
Executive/Board ChangesShareholder Meetings
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
Positive
Jun 4, 2026
Denali Therapeutics Inc. held its annual meeting of stockholders on June 3, 2026, with 86.96% of outstanding common shares represented in person or by proxy. Stockholders elected three Class III directors—Jennifer Cook, David Schenkein, M.D....
Business Operations and Strategy
Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
Negative
May 22, 2026
Denali Therapeutics Inc., based in South San Francisco, is a biotechnology company developing a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle platform. With a portfolio spanning multi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.